Welcome to our new Website! If you experience problems logging in, please contact us by email at support@south-bay-bio.com or by phone at (415) 935-3226 immediately for assistance!
Catalog number: SBB-KP0037, 100 x 50 μL
This kit is designed to test for specific activity of 20S immunoproteasome. The kit provides purified 20S immunoproteasome and is designed to test for Chymotrypsin-like activity (Suc-LLVY-AMC), and Caspase-like activity of the immunoproteasome subunits ß1i/ PSMB9 (PAL-AMC), and ß5i/PSMB8 (ANW-AMC). Additionally, we have included the compound, ONX-0914, which can be used to inhibit specifically the subunit ß5i/LMP7 20S immunoproteasome. All peptide substrates are conjugated to AMC, which upon proteasome catalyzed hydrolyses display fluorescence at Excitation = 345 nm, Emission = 445 nm; allowing for a real-time read out of 20S immunoproteasome specific activity.
$525.00
Catalog number: SBB-KP0037, 100 x 50 μL
This kit is designed to test for specific activity of 20S immunoproteasome. The kit provides purified 20S immunoproteasome and is designed to test for Chymotrypsin-like activity (Suc-LLVY-AMC), and Caspase-like activity of the immunoproteasome subunits ß1i/ PSMB9 (PAL-AMC), and ß5i/PSMB8 (ANW-AMC).
Quantity
Total
$525.00
Free Same-day Shipping on Domestic Orders over $750
| Quantity: | 100 x 50 μL reactions |
|---|---|
| Molecular Weight: | — |
| Purity: | > 95% |
| Readout: | Endpoint / Kinetic |
| Label or Dye: | 7-Amino-4-methylcoumarin |
| Detection Method: | Fluorescence |
| Substrate Properties: | Protein-Based Substrate |
| Storage Buffer: | — |
| Storage | -80C, Avoid multiple freeze / thaw cycles. It is recommended to make aliquots of each reaction component upon first time use. |
Certificate of Analysis
Open Certificate in New TabCitations and References
1) Singh, Pradeep K., et al. “Immunoproteasome ß5iSelective Dipeptidomimetic Inhibitors.” ChemMedChem 11.19 (2016): 2127-2131. 2) De Groot, Karina A., et al. “Pharmacodynamic monitoring of (immuno) proteasome inhibition during bortezomib treatment of a critically ill patient with lupus nephritis and myocarditis.” Lupus science & medicine 2.1 (2015): e000121. 3) Cornish Carmony, Kimberly, et al. “Elucidating the Catalytic Subunit Composition of Distinct Proteasome Subtypes: A Crosslinking Approach Employing Bifunctional Activity Based Probes.” ChemBioChem 16.2 (2015): 284-292. 4) Park, Ji Eun, et al. “PSMB9 codon 60 polymorphisms have no impact on the activity of the immunoproteasome catalytic subunit B1i expressed in multiple types of solid cancer.” PloS one 8.9 (2013): e73732. 5) Miller, Zachary, et al. “Inhibitors of the immunoproteasome: current status and future directions.” Current pharmaceutical design 19.22 (2013): 4140-4151. 6) Dubiella, Christian. Development and Characterization of Selective Immunoproteasome Inhibitors. Diss. Universität München, 2015.
